Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 10
2005 19
2006 11
2007 7
2008 8
2009 8
2010 7
2011 4
2012 2
2013 4
2014 1
2017 1
2018 1
2019 1
2020 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Unknown field was ignored: [Corporate Author]
Page 1
Believe-it then PROVE-IT.
Jackson G. Jackson G. Int J Clin Pract. 2004 Apr;58(4):325-6. doi: 10.1111/j.1368-5031.2004.00220.x. Int J Clin Pract. 2004. PMID: 15161113 No abstract available.
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Murphy SA, et al. J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62. doi: 10.1016/j.jacc.2009.10.005. J Am Coll Cardiol. 2009. PMID: 20082923 Free article. Clinical Trial.
BACKGROUND: In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial, more intensive lipid lowering with high-dose atorvastatin reduced the first o …
BACKGROUND: In the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Thera …
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR, Giugliano RP, Mohanavelu S, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Giraldez RR, et al. J Am Coll Cardiol. 2008 Sep 9;52(11):914-20. doi: 10.1016/j.jacc.2008.05.046. J Am Coll Cardiol. 2008. PMID: 18772061 Free article. Clinical Trial.
METHODS: We compared 2-year composites of death, myocardial infarction (MI), unstable angina, revascularization >30 days, and stroke (primary end point), and CHD death, MI, and revascularization >30 days (secondary end point) in 2,986 statin-naive patients with recent acute …
METHODS: We compared 2-year composites of death, myocardial infarction (MI), unstable angina, revascularization >30 days, and stroke (pri …
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
McLean DS, Ravid S, Blazing M, Gersh B, Shui A, Cannon CP. McLean DS, et al. Am Heart J. 2008 Feb;155(2):298-302. doi: 10.1016/j.ahj.2007.10.024. Am Heart J. 2008. PMID: 18215600 Clinical Trial.
Several observational studies have suggested that statins, presumably through their anti-inflammatory properties, decrease the risk of AF. METHODS: We analyzed 2 large, randomized trials, PROVE IT-TIMI 22 and phase Z of the A to Z trial, which compared lower- versus …
Several observational studies have suggested that statins, presumably through their anti-inflammatory properties, decrease the risk of AF. M …
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES, de Lemos JA, Cannon CP, Wiviott SD, Murphy SA, Morrow DA, Sabatine MS, Banerjee S, Blazing MA, Califf RM, Braunwald E. Brilakis ES, et al. Am J Cardiol. 2008 Sep 1;102(5):552-8. doi: 10.1016/j.amjcard.2008.04.024. Epub 2008 Jun 12. Am J Cardiol. 2008. PMID: 18721511 Clinical Trial.
We examined the effects of intensive statin therapy in patients with acute coronary syndromes (ACSs) and previous coronary artery bypass graft surgery (CABG) participating in the Pravastatin or Atorvastatin Evaluation and Infection Therapy …
We examined the effects of intensive statin therapy in patients with acute coronary syndromes (ACSs) and previous coronary artery byp …
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
Tung P, Wiviott SD, Cannon CP, Murphy SA, McCabe CH, Gibson CM. Tung P, et al. Am J Cardiol. 2009 Apr 15;103(8):1056-60. doi: 10.1016/j.amjcard.2008.12.034. Epub 2009 Feb 21. Am J Cardiol. 2009. PMID: 19361589 Clinical Trial.
Median high-density lipoprotein cholesterol was 43 mg/dl in summer versus 41 mg/dl in winter in the pravastatin group and 42 mg/dl in summer versus 39 mg/dl in winter in the atorvastatin group (p <0.001). More patients achieved LDL cholesterol <100 mg/dl in su …
Median high-density lipoprotein cholesterol was 43 mg/dl in summer versus 41 mg/dl in winter in the pravastatin group and 42 mg/dl in …
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial.
Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM, Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DI. Morrow DA, et al. Am Heart J. 2008 Jan;155(1):49-55. doi: 10.1016/j.ahj.2007.08.018. Epub 2007 Nov 1. Am Heart J. 2008. PMID: 18082488 Free PMC article. Clinical Trial.
METHODS: We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) …
METHODS: We performed a nested case-control study (n = 237 case-control pairs) among patients enrolled in the Pravastatin or Atorv …
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial.
Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 Trial Investigators. Bangalore S, et al. Circulation. 2010 Nov 23;122(21):2142-51. doi: 10.1161/CIRCULATIONAHA.109.905687. Epub 2010 Nov 8. Circulation. 2010. PMID: 21060068 Clinical Trial.
BACKGROUND: Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this population relative to cardiovascular outcomes. METHODS AND RESULTS: We evaluated 4162 patients enrolled in the PRavastatin Or …
BACKGROUND: Aggressive blood pressure (BP) control has been advocated in patients with acute coronary syndrome, but few data exist in this p …
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Gibson CM, et al. J Am Coll Cardiol. 2009 Dec 8;54(24):2290-5. doi: 10.1016/j.jacc.2009.09.010. J Am Coll Cardiol. 2009. PMID: 19958964 Free article. Clinical Trial.
METHODS: Outcomes were compared in 2,868 patients who underwent PCI for ACS just prior to enrollment in the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) tr …
METHODS: Outcomes were compared in 2,868 patients who underwent PCI for ACS just prior to enrollment in the PROVE IT-TIMI 22 ( …
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. O'Donoghue M, et al. Circulation. 2006 Apr 11;113(14):1745-52. doi: 10.1161/CIRCULATIONAHA.105.612630. Epub 2006 Mar 14. Circulation. 2006. PMID: 16537575 Clinical Trial.
METHODS AND RESULTS: Plasma levels of Lp-PLA2 activity were measured at baseline (n=3648) and 30 days (n=3265) in patients randomized to atorvastatin 80 mg/d or pravastatin 40 mg/d after ACS in the PROVE IT-TIMI 22 (PRavastatin Or atorVastati …
METHODS AND RESULTS: Plasma levels of Lp-PLA2 activity were measured at baseline (n=3648) and 30 days (n=3265) in patients randomized to …
83 results